MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

Trial status

Accepting patients

Phase

Phase 2

Enrollment

480

Last Updated

2 months ago

Patient Screener

Participating Centers

There are 7 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Talquetamab is a bispecific antibody that binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Talquetamab (No Prior T Cell Redirection Therapies)

Accepting patients

Talquetamab (Prior T Cell Redirection Therapies)

Accepting patients

Talquetamab Bi-Weekly

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.